Table 2.

Clinical overview of BORSA cases involved in 2014–2016 outbreak analysis

Patient	Year	Medical history	BORSA infection	Antibiotic pretreatment
P1: F, 52y	2014	Keratosis follicularis	Cellulitis of both ears with alternating BORSA-positive cultures and chronic BORSA carrier	Flucloxacillin oral course
P2: M, 76y	2015	Recurrent squamous cell carcinoma	Infection of wound after excision of skin carcinoma	Cotrimoxazol oral course. Fusidic acid topical course
P3: F, 46y	2016	Acute undifferentiated leukaemia, 6 months after SCT, GvHD skin	Cellulitis, secondary infecion of GvHD of the skin, small abscess of the axilla	Cotrimoxazol oral course
P4: M, 27y	2016	Eczema, aortic prosthetic valve due to congenital heart disease	Recurrent MSSA endocarditis with involvement of prosthetic material. Patient was initially treated with high-dose flucloxacillin and during the fourth episode of recurrence a BORSA was identified and treatment switched to vancomycin after 5 days. Fatal outcome	Three high-dose flucloxacillin i.v. courses of 6–8 weeks followed by oral clindamycin
P5; F, 58y	2016	Psoriasis, SLE, diabetic foot	Infected ulcers on the foot, cellulitis	Flucloxacillin and clindamycin oral course
P6: M, 22y	2016	Eczema	Infected eczema	No pre-treatment
P7: M, 79y	2016	Late-onset eczema	Ecthyma form of impetigo located on the hand	No pre-treatment
P8: M, 23Y	2015	Kidney transplantation	S. aureus bacteraemia and possible endocarditis originating from an infected venous line, complete recovery	Unkown

Year, most recent year with positive cultures available; antibiotic pretreatment, antibiotics received in the year prior to BORSA infection; F, female; M, male; y, years; SCT, stem cell transplantation; GvHD, graft versus host disease; SLE, systemic lupus erythematosis.